Unlocking Heart Health: New GLP-1 Research Reveals Cardiovascular Advantages
Tirzepatide Shows Promise in Reducing cardiovascular Risk for Obese heart Failure Patients A new analysis of the SUMMIT trial reveals that the glucagon-like peptide 1 (GLP-1) agonist tirzepatide significantly lowers the risk of cardiovascular (CV) events in patients with obesity and heart failure with preserved ejection fraction (HFpEF). This benefit remains consistent nonetheless of whether … Read more